Genetic mutations behind Covid susceptibility in India: BHU researchers

A team of researchers at the Banaras Hindu University (BHU) have discovered that multiple genetic mutations could be responsible for the Covid-19 susceptibility in India.

Omicron, Covid, Coronavirus, Covid-19
The study has been published in the international journal "Infection, Genetics, and Evolution".
IANS Varanasi
2 min read Last Updated : Jan 10 2022 | 9:40 AM IST

A team of researchers at the Banaras Hindu University (BHU) have discovered that multiple genetic mutations could be responsible for the Covid-19 susceptibility in India.

The team led by Professor Gyaneshwer Chaubey analysed the TMPRSS2 gene among global populations and found out that it accounted for the Covid-19 severity in the Indian population.

The study has been published in the international journal "Infection, Genetics, and Evolution".

Professor Chaubey said that the coronavirus (SARS-CoV2), the causative agent for Covid-19, employs the ACE2 receptor to enter the host cell through S protein, priming by a serine protease, TMPRSS2.

Mutation in the ACE2 and TMPRSS2 genes accounts for the disparity in disease susceptibility between populations.

The team also included Professor Chaubey's lab scientists Rudra Kumar Pandey, Anshika Srivastava, and Prajjval Pratap Singh.

He said that the team analysed next-generation sequencing (NGS) data of 393 global samples.

"Our analysis of phylogenetic relatedness showed a closer affinity of South Asians with the West Eurasian populations; therefore, host disease susceptibility and severity, particularly in the context of TMPRSS2, will be closer to West Eurasian instead of East Eurasians," said Rudra Kumar Pandey, the first author of the study.

The study has also reported a mutation rs2070788 which significantly increases TMPRSS2 expression in lungs and is associated with the high case fatality rate among Indian populations.

"Thus, ACE2 and TMPRSS2 have an antagonistic role in determining Covid-19 susceptibility among South Asians," said Professor Chaubey.

--IANS

amita/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusOmicronCoronavirus VaccineBHU

First Published: Jan 10 2022 | 9:40 AM IST

Next Story